Ozempic Gastroparesis Settlement: Statute of Limitations for Ozempic in Arizona

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From Mass Production Health Communication to Targeted Risk Assessment

The legacy of mass production in health and science communication has long centered on broad public awareness, drawing from historical contexts such as wartime logistics and medical preparedness. This heritage, exemplified by the meticulous documentation of operations like the US 380th Bomb Group’s use of code-named equipment or the strategic planning behind commando raids, underscores a tradition of translating complex operational data into actionable knowledge. In the general health domain, this approach has informed public understanding of risk factors and preventive measures, relying on clear, evidence-based narratives. Transitioning from this foundation, the focus now narrows to a specific occupational exposure concern: the potential link between Ozempic use and gastroparesis risk. In mass production environments—such as pharmaceutical manufacturing or healthcare distribution—workers may encounter heightened exposure to active ingredients or related compounds. This shift requires applying the same rigorous, neutral analytical lens used in historical health communications to assess exposure patterns, without delving into mechanistic disease claims. The goal is to pivot from general health literacy to a targeted evaluation of how occupational settings might influence risk profiles, maintaining the academic tone that prioritizes factual reporting over speculative inference. This transition respects the legacy of systematic information dissemination while addressing contemporary exposure dynamics.

Clinical Presentation and Diagnosis of Gastroparesis

Gastroparesis presents with symptoms such as nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, which measures the rate of gastric emptying after a radiolabeled meal. The condition can lead to malnutrition, weight loss, and impaired quality of life. In the context of Ozempic use, gastrointestinal adverse reactions are well-documented. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additionally, gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While gastroparesis is not explicitly listed in these tables, the spectrum of gastrointestinal symptoms, particularly delayed gastric emptying, is consistent with the drug's known effects.

Mechanistic Pathways and Warning Adequacy

The mechanistic pathway linking Ozempic to gastroparesis involves its action as a GLP-1 receptor agonist. GLP-1 receptors are expressed in the gastrointestinal tract and central nervous system, and activation slows gastric emptying by inhibiting antral contractions and stimulating pyloric tone. This pharmacodynamic effect is intended to reduce postprandial glucose excursions but can become pathological, leading to gastroparesis in susceptible individuals. The drug's labeling does not specifically warn about gastroparesis, but it does caution about serious hypersensitivity reactions, including anaphylaxis and angioedema, which have been reported with Ozempic and other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The adequacy of warnings regarding Ozempic and gastroparesis is a key risk anchor. The labeling describes gastrointestinal adverse reactions in general terms but does not explicitly mention gastroparesis as a potential adverse effect. This omission may affect patients' ability to recognize symptoms early and seek medical attention, potentially delaying diagnosis and treatment.

Statute of Limitations and Settlement Considerations for Arizona Patients

For affected patients in Arizona, settlement-related considerations are relevant. The statute of limitations for personal injury claims in Arizona is generally two years from the date the injury is discovered or should have been discovered. For Ozempic-related gastroparesis, the timeline between exposure and documented harm is critical. Patients may have used Ozempic for months or years before developing symptoms, and the diagnosis may be delayed due to the nonspecific nature of gastrointestinal complaints. The statute of limitations may begin when the patient is diagnosed with gastroparesis and becomes aware of the potential link to Ozempic. However, if the drug's labeling did not adequately warn about this risk, the statute may be tolled or extended under certain circumstances, such as fraudulent concealment. Patients should consult with a legal professional to determine their specific rights. Settlement considerations also include the strength of the evidence linking Ozempic to gastroparesis. While clinical trials show a higher incidence of gastrointestinal adverse reactions with Ozempic compared to placebo, the specific diagnosis of gastroparesis is not separately reported. However, the mechanistic plausibility and case reports in the medical literature may support claims. The adequacy of warnings is a central issue; if the manufacturer failed to provide sufficient information about the risk of gastroparesis, patients may have a stronger case for compensation. Settlement amounts may cover medical expenses, lost wages, pain and suffering, and other damages.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in Arizona?

In Arizona, the statute of limitations for personal injury claims is generally two years from the date the injury is discovered or should have been discovered. For Ozempic-related gastroparesis, this may begin when the patient is diagnosed and becomes aware of the potential link to the drug. However, if the manufacturer failed to adequately warn about the risk, the statute may be tolled or extended. Patients should consult a legal professional for their specific situation.

Does Ozempic cause gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying. While clinical trials do not explicitly list gastroparesis as an adverse reaction, the drug is associated with gastrointestinal symptoms such as nausea, vomiting, and delayed gastric emptying, which are consistent with gastroparesis. The labeling does not specifically warn about gastroparesis, but the mechanistic plausibility supports a potential link.

What evidence links Ozempic to gastroparesis?

Clinical trials show a higher incidence of gastrointestinal adverse reactions with Ozempic compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The drug's mechanism as a GLP-1 agonist slows gastric emptying, which can become pathological. While gastroparesis is not separately reported, the symptom profile and case reports in medical literature support the association.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Labeling

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.